Short answer · Medically reviewed summary · Last updated: 2026-05-08
A pituitary tumour is an abnormal growth in the pituitary gland, a condition first systematically identified in the late 19th century as medical imaging and endocrine science emerged. Today, understanding of a pituitary tumour has shifted from viewing it as a mysterious cause of physical deformity to a manageable condition treated through precise neurosurgery, targeted medication, and advanced hormonal therapy. When was the pituitary tumour first described? While ancient physicians noted physical changes associated with pituitary disorders, the first formal clinical description of a pituitary tumour is often credited to Pierre Marie in 1886, who described acromegaly.
A pituitary tumour is an abnormal growth in the pituitary gland, a condition first systematically identified in the late 19th century as medical imaging and endocrine science emerged. Today, understanding of a pituitary tumour has shifted from viewing it as a mysterious cause of physical deformity to a manageable condition treated through precise neurosurgery, targeted medication, and advanced hormonal therapy.
While ancient physicians noted physical changes associated with pituitary disorders, the first formal clinical description of a pituitary tumour is often credited to Pierre Marie in 1886, who described acromegaly. Shortly after, in 1889, Oskar Minkowski linked these physical changes to the pituitary gland itself. For decades, these growths were often misdiagnosed or attributed to constitutional factors until the development of modern endocrinology revealed that a pituitary tumour could disrupt the body's entire hormonal balance.
The 20th century transformed the management of a pituitary tumour from a high-risk surgical endeavor into a highly specialized field. Early surgeons like Harvey Cushing, considered the father of modern neurosurgery, pioneered the transsphenoidal approach in the early 1900s, which remains the gold standard for reaching a pituitary tumour today.
Modern clinical geneticists now understand that while most cases are sporadic, certain hereditary syndromes—such as Multiple Endocrine Neoplasia type 1 (MEN1)—can predispose individuals to a pituitary tumour. Genetic screening now allows for earlier detection and proactive monitoring within affected families, shifting the paradigm from reactive treatment to preventative care.
Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.